Cartesian Therapeutics, Inc. Balance Sheet
RNAC|8 years of annual SEC 10-K data (FY2016-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 8 fiscal years. All figures from audited SEC 10-K filings.
Cartesian Therapeutics, Inc. had $296M in total assets with negative shareholders' equity of $7M as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2016 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $125.1M | $212.6M | $76.9M | $114.1M | $138.7M | $89.9M | $37.4M | $16.6M |
| Accounts Receivable | $1.1M | $872.0K | $5.9M | $6.6M | $9.9M | $7.2M | $5.0M | $215.0K |
| Current Assets | $129.3M | $216.6M | $90.7M | $148.1M | $144.4M | $151.3M | $96.7M | $86.8M |
| PP&E (Net) | $12.2M | $9.9M | $2.1M | $2.8M | $2.1M | $1.4M | $1.2M | $2.0M |
| Goodwill | $48.2M | $48.2M | $48.2M | - | - | - | - | - |
| Total Assets | $296.4M | $435.0M | $305.1M | $165.9M | $159.9M | $165.4M | $99.6M | $89.3M |
| Current Liabilities | $14.9M | $23.0M | $68.2M | $25.1M | $72.3M | $81.5M | $34.9M | $13.7M |
| Shareholders' Equity | -$6.8M | -$440.2M | $93.8M | -$18.0M | $8.4M | -$5.4M | $51.8M | -$87.8M |